key: cord-0741539-ob9l68g2 authors: Asadi‐Pooya, Ali A.; Emami, Amir; Akbari, Ali; Javanmardi, Fatemeh title: COVID‐19 presentations and outcome in patients with epilepsy date: 2021-02-16 journal: Acta Neurol Scand DOI: 10.1111/ane.13404 sha: 820e6ee1e7ac6a9cf45b8280d1d408e60b860b2d doc_id: 741539 cord_uid: ob9l68g2 OBJECTIVE: To determine whether patients with epilepsy (PWE) are particularly over‐represented in a very large cohort of patients with COVID‐19. We also investigated whether COVID‐19 is associated with a different clinical picture or a more severe course of illness in PWE (compared with others). METHODS: All consecutive patients who referred to and admitted at healthcare facilities anywhere in Fars province (located in the south of Iran with a population of 4,851,000 people) from February 19, 2020 until November 20, 2020 were included. RESULTS: A total of 37,968 patients were studied. Eighty‐two patients (0.2%) had pre‐existing epilepsy. Seizures were significantly more frequent among PWE as a presenting manifestation of COVID‐19 compared with that in people without epilepsy (Odds Ratio = 27; p = 0.0001). Furthermore, PWE less often reported cough (significantly) and more often had gastrointestinal symptoms (vomiting and anorexia; as trends) compared with those in people without epilepsy. Patients with epilepsy were not differently likely to be intubated or admitted at ICUs. Case fatality rates were not different between the two groups [9.8% in PWE and 8.5% in people without epilepsy; p = 0.690]. CONCLUSION: Patients with epilepsy are not susceptible to contracting COVID‐19 more than other individuals. Furthermore, COVID‐19 in PWE is not associated with a more severe illness or a poorer prognosis. However, PWE and COVID‐19 may present somewhat differently than others with such an illness. Why PWE less often present with cough and more often present with gastrointestinal symptoms is not clear yet and should be investigated and clarified in the future studies. Shiraz University and Shiraz University of Medical Sciences had no role in the study design, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication Objective: To determine whether patients with epilepsy (PWE) are particularly overrepresented in a very large cohort of patients with COVID-19. We also investigated whether COVID-19 is associated with a different clinical picture or a more severe course of illness in PWE (compared with others). Methods: All consecutive patients who referred to and admitted at healthcare facilities anywhere in Fars province (located in the south of Iran with a population of 4,851,000 people) from February 19, 2020 until November 20, 2020 were included. Results: A total of 37,968 patients were studied. Eighty-two patients (0.2%) had pre-existing epilepsy. Seizures were significantly more frequent among PWE as a presenting manifestation of COVID-19 compared with that in people without epilepsy (Odds Ratio = 27; p = 0.0001). Furthermore, PWE less often reported cough (significantly) and more often had gastrointestinal symptoms (vomiting and anorexia; as trends) compared with those in people without epilepsy. Patients with epilepsy were not differently likely to be intubated or admitted at ICUs. Case fatality rates were not different between the two groups [9.8% in PWE and 8.5% in people without epilepsy; p = 0.690]. Patients with epilepsy are not susceptible to contracting COVID-19 more than other individuals. Furthermore, COVID-19 in PWE is not associated with a more severe illness or a poorer prognosis. However, PWE and COVID-19 may present somewhat differently than others with such an illness. Why PWE less often present with cough and more often present with gastrointestinal symptoms is not clear yet and should be investigated and clarified in the future studies. coronavirus, COVID, epilepsy, mortality, seizure caregivers, and the scientific community to know whether they are at increased risk of contracting COVID-19, and also whether this viral infection might cause a more severe illness, should it happen in PWE. The first confirmed cases of COVID-19 were reported in Iran on February 19, 2020. As of January 2, 2021 there has been 55,337 COVID-19-related deaths with 1,231,429 confirmed infections in Iran. 7 The aim of the current study was to determine whether PWE are particularly over-represented (significantly more than 1% rate, which is the prevalence rate of epilepsy in Iran) in a very large cohort of patients with COVID-19; this might help us conclude on their susceptibility to contracting this viral infection. We also investigated whether COVID-19 is associated with a different clinical picture or a more severe course of illness in PWE (compared with others). In this study, all consecutive patients who referred to and admitted For all patients, who were admitted with a diagnosis of COVID-19, the following data were collected at the emergency room by the admitting physician and entered into a database (on admission): age, sex, presence of fever, cough, respiratory distress, muscle pain, dizziness, headache, loss of smell, seizure, abdominal pain, nausea, vomiting, and anorexia. Other collected data included: real-time polymerase chain reaction test results, chest CT scan results, the need for intubation, and admission to a hospital ward (i.e., COVIDspecific ward, intensive care unit [ICU], or others). Underlying chronic health problems were also collected (self-declared) (e.g., renal, liver, cardiac, neurological disorders [including epilepsy]). No data were available about the hospital course of the patients (e.g., laboratory test results, complications). However, the outcome was also recorded in the database, as dead or discharged. This was a nested case-control study. All the statistical analyses were performed by SPSS software version 22. Values were presented as mean ± standard deviation (SD) for continuous variables and as number (percent) of subjects for categorical variables. Fisher's exact test (FE), Pearson's chi-square (PCS), and t-test were used for univariate comparisons. The associations between pre-existing epilepsy with other variables were determined using the logistic regression analysis; the variables with p < 0.1 from the univariate analyses were entered into the logistic regression analysis model. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. A p value less than 0.05 (2-sided) was considered as significant. In total, 3229 patients died (case fatality rate = 8.5%). Eighty-two patients (0.2%) had pre-existing epilepsy, 1004 patients Table 1 shows the clinical manifestations of COVID-19 (on admission) in PWE compared with those in people without epilepsy. We included all the variables with a p value <0.1 in a regression analysis model. The results of the binary logistic regression analysis are shown in Table 2 (only the significant associations or trends). The model that was generated by this test was significant Table 2 ). Patients with epilepsy were not differently likely to be intubated In this study, we observed that PWE are not over-represented (significantly more than 1% rate) in a very large cohort of patients with COVID-19. In one previous study, among 5700 PWE, who were managed at the studied centers, only 14 patients (0.2%) tested positive for SARS-CoV2. 4 Their rate is similar to our observation, and their study corroborates our finding. While another study suggested that the cumulative incidence of COVID-19 in PWE was higher compared with that in the population without epilepsy (1.2% vs. 0.5%), 3 We observed that PWE and COVID-19 may present differently one patient with epilepsy was included in that study. 10 In a previous study, 18% of PWE reported seizure worsening, which was best explained by the number of anti-seizure medications (ASMs) and the severity of sleep disorder. 11 Exacerbation or breakthrough seizures in PWE and COVID-19 may be a multifactorial phenomenon. SARS-CoV2 may have neurotropism, and COVID-19 has been associated with seizures (even in people without pre-existing epilepsy) in many previous studies. 12 Furthermore, this pandemic has caused significant disruption in the quality and availability of care to PWE, as well as increased stress and social isolation rates; these may contribute to exacerbation or breakthrough seizures in PWE. 11, 13 Finally, some patients with COVID-19 may develop a seizure as a consequence of hypoxemia, organ failure, metabolic derangements, or drug-drug interactions. 14 The pre-existing medical conditions were based on self-declaration, and no validation was done. Furthermore, we did not have access to the whole medical records of the patients to clarify the complete clinical picture and also the course of illness in these patients. Based on the current study, we can suggest that PWE are not susceptible to contracting COVID-19 more than that in other individuals. Similarly, we may conclude that COVID-19 in PWE is not associated with a more severe illness or a poorer prognosis. However, PWE and COVID-19 may clinically present somewhat differently than others with such an illness. Why PWE less often present with cough and more often present with gastrointestinal symptoms is not clear yet and should be investigated and clarified in the future studies. Shiraz University of Medical Sciences supported this study. analyzed the data; drafted and revised the manuscript. Others: Collected the data and revised the manuscript. The data are confidential and will not be shared as per the regulations of Shiraz University of Medical Sciences. Ali A. Asadi-Pooya https://orcid.org/0000-0002-2598-7601 The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak Prevalence of underlying diseases in died cases of COVID-19: a systematic review and meta-analysis Incidence and case fatality rate of COVID-19 in patients with active epilepsy Did the COVID-19 pandemic silence the needs of people with epilepsy? Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies Epilepsy syndromes in Iran: a systematic review Solid organ transplantation in the era of COVID-19: lessons from the past six months Adrenocorticotropic hormone for the treatment of West Syndrome in children Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: a systematic review Epilepsy care in the time of COVID-19 pandemic in Italy: risk factors for seizure worsening COVID-19, de novo seizures, and epilepsy: a systematic review Impacts of the COVID-19 pandemic on Iranian patients with epilepsy Seizures associated with coronavirus infections Prevalence, mechanisms, and implications of gastrointestinal symptoms in COVID-19